Welcome to our dedicated page for Alkermes news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes stock.
Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Alkermes plc (Nasdaq: ALKS) reported financial results for the quarter and year ended Dec. 31, 2021, showing total revenues of $324.5 million for Q4 2021 and $1.17 billion for the year, reflecting a year-over-year increase. Net income for Q4 was $0.9 million, a significant turnaround from a net loss of $42.6 million in the same quarter of the previous year. However, the company anticipates a GAAP net loss of $180 to $210 million for 2022, primarily due to the expected loss of royalties from long-acting INVEGA products. Alkermes aims to drive long-term profitability and shareholder value creation.
Alkermes announces positive topline results from the ENLIGHTEN-Early phase 3b study of LYBALVI (olanzapine and samidorphan) in young adults (ages 16-39) with schizophrenia, schizophreniform disorder, or bipolar I disorder. The study met its primary endpoint, showing less weight gain in patients treated with LYBALVI (mean: 4.91%) compared to olanzapine (mean: 6.77%, p=0.012) at week 12. Secondary endpoints also favored LYBALVI in weight gain percentages and symptom severity. Safety profiles were consistent with prior studies, with a majority of patients completing the trial.
Alkermes plc (Nasdaq: ALKS) will conduct a conference call on February 16, 2022, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2021 financial results. The call will provide insights into the company's financial expectations for 2022 and include an operational update. Investors can access the webcast and slides via the Investors section on Alkermes' website. Dial-in details for U.S. and international callers are provided. A replay will be available shortly after the event.
Alkermes plc (Nasdaq: ALKS) announced its presentation of clinical data on nemvaleukin alfa, an investigational IL-2 variant immunotherapy, at the ASCO Gastrointestinal Cancers Symposium from Jan. 20-22, 2022. The poster will feature findings from the ARTISTRY-1 phase 1/2 study, evaluating nemvaleukin's efficacy and tolerability alone and with KEYTRUDA in advanced GI cancers. The abstract number is 659, presented by Dr. Ulka N. Vaishampayan. Nemvaleukin aims to enhance tumor-killing immune cells while minimizing immunosuppression.
Summary not available.
Alkermes plc (Nasdaq: ALKS) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 a.m. EST. CEO Richard Pops will lead the presentation, followed by a Q&A session. The event will be accessible via live webcast on the company's investor relations page and archived for 14 days. Alkermes is focused on developing innovative medicines in neuroscience and oncology, with a portfolio aimed at addiction, schizophrenia, and bipolar I disorder.
Alkermes plc (Nasdaq: ALKS) announced its participation in the fourth annual Evercore ISI HealthCONx Conference on December 2, 2021, at 10:30 a.m. ET. The event will be accessible under the Investors section of Alkermes' website and archived for 14 days. Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience and oncology, with a pipeline targeting neurodegenerative disorders and cancer.
Alkermes plc (Nasdaq: ALKS) has appointed Cato T. Laurencin, M.D., Ph.D., as a new independent director to its Board. Dr. Laurencin is a distinguished academic and pioneer in regenerative engineering with a strong focus on public health and social justice. His appointment, welcomed by CEO Richard Pops, is expected to enhance the company’s innovation and shareholder value creation strategies. Alex Denner of Sarissa Capital views this as a positive outcome for shareholders, anticipating a fresh perspective and improved operational excellence.
Alkermes plc (Nasdaq: ALKS) has initiated a Phase 1 study for ALKS 1140, an investigational HDAC inhibitor aimed at treating neurodegenerative disorders. The study's first subject has been dosed, targeting safety and tolerability in healthy adults. ALKS 1140 is designed to enhance synaptic function, addressing significant unmet medical needs. The trial will involve up to 80 volunteers in Australia and assess pharmacokinetics and pharmacodynamics, marking a crucial step in Alkermes’ clinical program.
Alkermes plc (Nasdaq: ALKS) will participate in a fireside chat at the Stifel Virtual Healthcare Conference on November 16, 2021, at 9:20 a.m. ET. Investors can access the presentation via the Investors tab on the company's website. Alkermes focuses on developing innovative medicines in neuroscience and oncology, with a range of products targeting addiction, schizophrenia, and bipolar I disorder. The company has R&D facilities in Massachusetts and manufacturing sites in Ireland and Ohio.